Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes

IF 2.9 3区医学 Q2 GENETICS & HEREDITY Pharmacogenomics Journal Pub Date : 2022-01-31 DOI:10.1038/s41397-022-00268-6

Jochen Fracowiak, Tatjana Huebner, Steffen Heß, Christoph Roethlein, Daria Langner, Udo Schneider, Felix Falkenberg, Catharina Scholl, Roland Linder, Julia Stingl, Britta Haenisch, Michael Steffens

{"title":"Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes","authors":"Jochen Fracowiak, Tatjana Huebner, Steffen Heß, Christoph Roethlein, Daria Langner, Udo Schneider, Felix Falkenberg, Catharina Scholl, Roland Linder, Julia Stingl, Britta Haenisch, Michael Steffens","doi":"10.1038/s41397-022-00268-6","DOIUrl":null,"url":null,"abstract":"The impact of genetic variability of pharmacogenes as a possible risk factor for adverse drug reactions is elucidated in the EMPAR (Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung/English: influence of metabolic profiles on the safety of drug therapy in routine care) study. EMPAR evaluates possible associations of pharmacogenetically predicted metabolic profiles relevant for the metabolism of frequently prescribed cardiovascular drugs. Based on a German study population of 10,748 participants providing access to healthcare claims data and DNA samples for pharmacogenetic assessment, first analyses were performed and evaluated. The aim of this first evaluation was the characterization of the study population with regard to general parameters such as age, gender, comorbidity, and polypharmacy at baseline (baseline year) as well as important combinations of cardiovascular drugs with relevant genetic variants and predicted metabolic phenotypes. The study was registered in the German Clinical Trials Register (DRKS) on July 6, 2018 (DRKS00013909).","PeriodicalId":54624,"journal":{"name":"Pharmacogenomics Journal","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2022-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975744/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics Journal","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41397-022-00268-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

The impact of genetic variability of pharmacogenes as a possible risk factor for adverse drug reactions is elucidated in the EMPAR (Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung/English: influence of metabolic profiles on the safety of drug therapy in routine care) study. EMPAR evaluates possible associations of pharmacogenetically predicted metabolic profiles relevant for the metabolism of frequently prescribed cardiovascular drugs. Based on a German study population of 10,748 participants providing access to healthcare claims data and DNA samples for pharmacogenetic assessment, first analyses were performed and evaluated. The aim of this first evaluation was the characterization of the study population with regard to general parameters such as age, gender, comorbidity, and polypharmacy at baseline (baseline year) as well as important combinations of cardiovascular drugs with relevant genetic variants and predicted metabolic phenotypes. The study was registered in the German Clinical Trials Register (DRKS) on July 6, 2018 (DRKS00013909).

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

根据选定药物基因的代谢表型评估 EMPAR 研究人群

EMPAR（Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung/英语：常规护理中代谢特征对药物治疗安全性的影响）研究阐明了药物基因的遗传变异作为药物不良反应的可能风险因素的影响。EMPAR 评估了药物基因预测代谢特征与常用心血管处方药代谢可能存在的关联。该研究以德国的 10748 名参与者为研究对象，这些参与者提供了医疗报销数据和用于药物基因评估的 DNA 样本，研究人员对这些数据进行了首次分析和评估。首次评估的目的是根据基线（基线年）时的年龄、性别、合并症、多重用药等一般参数，以及心血管药物的重要组合、相关基因变异和预测代谢表型，确定研究人群的特征。该研究于2018年7月6日在德国临床试验注册中心（DRKS）注册（DRKS00013909）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmacogenomics Journal 医学-药学

CiteScore

7.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Pharmacogenomics Journal is a print and electronic journal, which is dedicated to the rapid publication of original research on pharmacogenomics and its clinical applications. Key areas of coverage include: Personalized medicine Effects of genetic variability on drug toxicity and efficacy Identification and functional characterization of polymorphisms relevant to drug action Pharmacodynamic and pharmacokinetic variations and drug efficacy Integration of new developments in the genome project and proteomics into clinical medicine, pharmacology, and therapeutics Clinical applications of genomic science Identification of novel genomic targets for drug development Potential benefits of pharmacogenomics.